Genitourinary Cancers | Specialty

Role of Cytoreductive Nephrectomy in mRCC

April 14th 2020

Avelumab sBLA Filed for Frontline Maintenance in Urothelial Carcinoma, Breakthrough Designation Granted

April 9th 2020

A supplemental Biologics License Application has been filed with the FDA for avelumab for the frontline maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma.

Cabozantinib Combinations Generate Excitement in RCC

April 8th 2020

Rana R. McKay, MD, discusses the evolving role of cabozantinib in the renal cell carcinoma treatment paradigm and the research being done examining novel combinations.

UGN-102 Active in Non-Muscle Invasive Bladder Cancer

April 3rd 2020

UGN-102 for intravesical solution induced a 65% complete response rate in patients with low-grade intermediate-risk non-muscle invasive bladder cancer.

Dr. Iyer on Challenges With Selecting Patients With Bladder Cancer for FGFR Inhibitors

April 3rd 2020

Gopa Iyer, MD, discusses the challenges faced with identifying an optimal screening methodology to select patients with bladder cancer for FGFR inhibitor therapy.

Dr. Mehrazin on Findings From the CARMENA Trial in Metastatic RCC

April 3rd 2020

Reza Mehrazin, MD, discusses the findings of the phase III CARMENA trial in metastatic renal-cell carcinoma.

Expert Highlights Breakthroughs and Next Steps in RCC Paradigm

April 2nd 2020

Matthew T. Campbell, MD, discusses the evolving treatment options in the renal cell carcinoma paradigm.

Dr. Bakouny on the Utility of Checkpoint Inhibitors in Sarcomatoid RCC

April 2nd 2020

Ziad Bakouny, MD, MSc, discusses the utility of checkpoint inhibitors in renal cell carcinoma with sarcomatoid differentiation.

Dr. Boorjian on Research With Nadofaragene Firadenovec in Nonmuscle Invasive Bladder Cancer

April 1st 2020

Stephen A. Boorjian, MD, professor of urology, Mayo Clinic, discusses research with intravesical nadofaragene firadenovec in patients with nonmuscle invasive bladder cancer (NMIBC).

Dr. Rosenberg on Enfortumab Vedotin/Pembrolizumab in Urothelial Carcinoma

April 1st 2020

Jonathan E. Rosenberg, MD, medical oncologist, chief, Genitourinary Medical Oncology Service, Memorial Sloan Kettering Cancer Center, discusses the updated results of the phase Ib/II EV-103 trial (NCT03288545) with enfortumab vedotin-ejfv (Padcev) and pembrolizumab (Keytruda) in patients with locally advanced or metastatic urothelial carcinoma.

FDA Approval Sought for Tivozanib in Relapsed/Refractory Renal Cell Carcinoma

April 1st 2020

A new drug application has been submitted to the FDA for tivozanib for the treatment of patients with relapsed/refractory renal cell carcinoma, according to Aveo Oncology, the company developing the VEGFR TKI.

PD-1 Inhibition Reigns Supreme in Frontline Advanced RCC

March 31st 2020

The role of immunotherapy in metastatic renal cell carcinoma has grown tremendously with dual immune checkpoint inhibition and combinations of anti–PD-1/VEGF inhibitors.

Sequencing Therapies After Progression of RCC

March 31st 2020

Treatment Options for Intermediate/Poor-Risk RCC

March 31st 2020

How to Manage Borderline Intermediate-Risk RCC

March 31st 2020

Favorable-Risk RCC: Options for VEGF TKI Monotherapy

March 31st 2020

Favorable-Risk RCC: Frontline VEGF TKI/IO Combinations

March 31st 2020

Favorable-Risk RCC: Factors in Selecting Therapy

March 31st 2020

Importance of Risk Assessment in Renal Cell Carcinoma

March 31st 2020

Renal Cell Carcinoma: Early Management Strategies

March 31st 2020